1044518-75-3

Basic information

• Product Name: (4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester
• Synonyms: (4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester
• CAS NO: 1044518-75-3
• Molecular Weight: 258.315
• Mol File: 1044518-75-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 320.3±32.0 °C(Predicted)
• Density: 1.073±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester(1044518-75-3)
• EPA Substance Registry System: (4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-acetic acid tert-butyl ester(1044518-75-3)

Safety Data

• Hazardous Substances Data: 1044518-75-3(Hazardous Substances Data)

Usage

Uses

3,5-Dideoxy-2,4-O-(1-methylethylidene)-D-erythro-hexuronic Acid 1,1-Dimethylethyl Ester is used in the synthesis of Amphotericin B.

Upstream product

• 144-55-8 sodium hydrogencarbonate 
• 148809-28-3 [(4S,6R)-2,2-dimethyl-6-hydroxymethyl-1,3-dioxan-4-yl]acetic acid t-butyl ester 

Downstream Products

• 1044518-76-4 tert-butyl 2-[(4S,6R)-6-((R)-3-((4S,6S)-6-(2-(benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxan-4-yl)-1-hydroxyprop-2-ynyl)-2,2-dimethyl-1,3-dioxan-4-yl]acetate 
• 289042-12-2 2-[(4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidin-5-yl]vinyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid tert butyl ester 
• 1378943-63-5 C₂₉H₄₀FN₃O₆S 

Relevant articles and documents

A statin intermediate and its derivatives

The invention discloses a preparation method of a statin intermediate and derivatives thereof. The preparation method comprises the steps of: preparing to obtain a compound in a formula (II) through oxidation reaction among a compound in a formula IV, DMSO (dimethylsulphoxide) and alkali in the existence of an alkali metal salt catalyst, and obtaining a compound in a formula (I) by base catalysis through condensation of the compound in the formula (II) and a compound in a formula (III), wherein in the formulas, X is halogens, R is substituted or non-substituted alkyl groups of C1-C6 and alkane cyclic groups or aryl groups of C3-C5, substituent groups of R are the aryl groups, and R1 is selected from one or several of the alkyl groups of C1-C6 and the halogens. Compared with the prior art, the preparation method has the advantages that the compound in the formula IV is not esterified and hydrolyzed for preparing alcohol, then aldehyde (compound in the formula II) is prepared through oxidation, and the compound in the formula II is directly prepared from the compound in the formula IV in one step. The preparation method has the advantages of short steps, simple operation and suitability for industrial production.

Synthesis of 35-deoxy amphotericin B methyl ester: A strategy for molecular editing

(Chemical Presented) A modular strategy for the assembly of amphotericin B analogues with modifications in the macrolactone ring relies on the efficient gram-scale synthesis of all major and minor motifs of amphotericin B. Proof of concept has been achieved by the preparation of the 35-deoxy aglycone en route to the long-sought-after 35-deoxy analogue of amphotericin B.